培哚普利对冠状动脉粥样硬化进展的长期影响:PERSPECTIVE(血管造影及血管内超声评价培哚普利对冠状动脉粥样硬化的前瞻性作用)研究  

Long-Term Effect of Perindopril on Coronary Atherosclerosis Progression(from the PERindopril’s Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation[PERSPECTIVE]Study)

作　　者：Rodriguez-Granillo G.A. Vos J. Bruining N. P.J. De Feyter 罗亮 

机构地区：[1]Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam,Netherlands.Dr

出　　处：《世界核心医学期刊文摘（心脏病学分册）》2007年第12期18-19,共2页

摘　　要：纳入12218例患者的多中心EUROPA试验表明,培哚普利可减少冠心病确诊患者的不良临床事件。PERSPECTIVE研究为EUROPA试验的一项亚研究,评估了培哚普利对冠状动脉粥样硬化斑块进展犤以定量冠状动脉血管造影和血管内超声(IVUS)评价犦的作用。研究共纳入244例患者(平均年龄57岁,男性占81%)。自96例随机分配使用培哚普利的患者和98例使用安慰剂的患者获得了可供评估的成对定量冠状动脉血管造影资料。The multicenter EUROPA trial of 12,218 patients showed that perindopril decreased adverse clinical events in patients with established coronary heart disease. The PERSPECTIVE study, a substudy of the EUROPA trial, evaluated the effect of perindopril on coronary plaque progression as assessed by quantitative coronary angiography and intravascular ultrasound(IVUS). In total 244 patients(mean age 57 years, 81% men) were included. Evaluable paired quantitative coronary angiograms were obtained from 96 patients ...

关 键 词：冠状动脉粥样硬化 安慰剂 患者 冠状动脉血管 PERSPECTIVE 空白剂 培哚普利 血管内超声 

分 类 号：R541.4[医药卫生—心血管疾病]